Skip to content

The impact of High-Definition transcranial direct current stimulation on depression, cognitive function and cerebellum GABA level in Parkinson's disease patients

The impact of High-Definition transcranial direct current stimulation on depression, cognitive function and cerebellum GABA level in Parkinson's disease patients based on MEGA-PRESS analysis

Status
Active, not recruiting
Phases
Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400093363
Enrollment
Unknown
Registered
2024-12-03
Start date
2024-12-31
Completion date
Unknown
Last updated
2024-12-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson's disease

Interventions

active stimulation group:Transcranial direct current stimulation combined with conventional cognitive training
sham stimulation group:sham transcranial direct current stimulation combined with conventional cognitive training

Sponsors

Nantong First People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
40 Years to 85 Years

Inclusion criteria

Inclusion criteria: 1.Aged between 40 and 85, gender not limited; 2.Meeting the diagnostic criteria for primary Parkinson's disease according to the Chinese Parkinson's Disease Guidelines (2016 edition); 3.The types and doses of anti-Parkinson's disease medications remain unchanged during the intervention period; 4.Hoehn-Yahr staging: I-III; 5.Mini-Mental State Examination (MMSE) score between 15 and 26, with no language communication barriers and capable of completing assessments; 6.Consent and sign the informed consent form to participate in this study.

Exclusion criteria

Exclusion criteria: 1.Secondary Parkinson's syndrome or Parkinson's plus syndrome caused by various factors; 2.Essential tremor, primary dystonia, and other diseases; 3.Individuals with severe cardiopulmonary diseases and hepatorenal dysfunction; 4.Patients with other diseases that may affect training (such as visual or auditory impairments, severe physical activity limitations, contraindications for exercise, or other factors that prevent cooperation in completing the trial); 5.Patients whose PD-related comorbid symptoms are considered by the clinician to significantly affect cognitive function testing; 6.Those currently undergoing other non-pharmacological interventions; 7.Individuals with implanted cardiac pacemakers, those who cannot remove various metal devices, those with metal clips left in the body after surgery, and those with claustrophobia or other conditions that prevent MRI examination.

Design outcomes

Primary

MeasureTime frame
Montreal Cognitive Assessment Score;

Secondary

MeasureTime frame
auditory verbal learning test—Huashan version score;trail making test score;symbol digit modalities test score;Hamilton Depression Scale Score;Hamilton Anxiety Scale Score;the level of GABA in the cerebellum;

Countries

China

Contacts

Public ContactChen weiguan

Nantong First People's Hospital

chenwg1982@163.com+86 138 1470 3625

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026